← board
MLYS
Mineralys Therapeutics Inc.distress 6/10 · elevated risk$26.05-4%today-45% from 52w high
Cardiovascular 3Nephrology 1
Lead: Hypertension · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$113M
Runway
0.8 yrs
Shares 1y
+24%
Price & events
-24.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.6%
1D
-3.8%
1W
+1.7%
1M
-8.6%
3M
-20.5%
6M
+95.7%
1Y
+94.1%
2Y
—
5Y
+41.3%
All
Overview
- Market Cap
- $2.15B
- Volume
- 172.35K
- 52 Week Range
- $12.87 – $47.33
- Total Shares
- 82.50M
- Float Shares
- 61.91M
- Short %
- 15.08%
- % Held by Insiders
- 0.66%
- % Held by Institutions
- 106.97%
- RVOL
- 0.13x
- Beta
- 0.65
Pipeline stages · 1 programs
lorundrostat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12-30 | Phase 3 | lorundrostat | Hypertension | 1076 | active not recruiting |
| 2025-12-17 | Phase 2 | Lorundrostat | Obstructive Sleep Apnea, Hypertension | 48 | completed |
| 2025-02-27 | Phase 2 | Lorundrostat 25mg, SGLT2i QD, Washout | Chronic Kidney Disease | 60 | completed |
| 2025-01-15 | Phase 2 | lorundrostat Dose 1, lorundrostat Dose 2 | Hypertension | 285 | completed |
Catalyst news & presentations · 9
- December 22, 2026Confirmed 100%PDUFAPDUFAlorundrostat · PDUFA target action dateSEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- first quarter of 2026readoutPhase 2lorundrostat · Topline results from Phase 2 Explore-OSA trial evaluating lorundrostat in participants with moderate to severe OSA and hypertension.SEC 8-K
- March 6, 2026filing acceptanceFiled (NDA/BLA)lorundrostat · FDA accepted NDA for lorundrostatSEC 8-K
- mid first half of 2025readoutPhase 3lorundrostat · Topline data for the Launch-HTN trial now anticipated in mid first half of 2025.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 2lorundrostat · Anticipated initiation of Phase 2 trial evaluating lorundrostat in subjects with moderate-to-severe OSA and hypertensionSEC 8-K
- first quarter of 2025readoutPhase 2lorundrostat · Topline data from pivotal Advance-HTN trialSEC 8-K
- 2025-01-08fda agreementlorundrostat · FDA cleared IND application for Phase 2 clinical trial in moderate-to-severe obstructive sleep apnea and hypertensionSEC 8-K
- October 30, 2024enrollment completesecondaryPhase 3lorundrostat · Completed enrollment in the Launch-HTN trial ahead of schedule.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $49 (+88% upside) · 8 analysts
- 2026-04-27TD CowenBuy
- 2026-03-13B of A SecuritiesBuy
- 2025-12-19StifelBuy
- 2025-11-12HC Wainwright & Co.Buy
- 2025-11-11Wells FargoOverweight
- 2025-10-30HC Wainwright & Co.Buy
Competitors — Hypertension
- LLYELI LILLY & Co$1094.4B · D3
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- INSMINSMED Inc$22.9B · D2
- SGPSpyGlass Pharma, Inc.$682M · D2
- TECXTectonic Therapeutic, Inc.$589M · D0
- TENXTENAX THERAPEUTICS, INC.$390M · D2
- IKTInhibikase Therapeutics, Inc.$289M · D4
- GALTGALECTIN THERAPEUTICS INC$231M · D5
- GOSSGossamer Bio, Inc.$33M · D5
Recent news
- 2026-07-21Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise - Stock Titan
- 2026-07-21Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com - Investing.com Canada
- 2026-07-21Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares - Investing.com
- 2026-07-21Mineralys Therapeutics, Inc. (MLYS): Analyst Consensus Points to a Promising 83% Upside Potential - DirectorsTalk Interviews
- 2026-07-21Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48 - Bitget
- 2026-07-18Form 144 Mineralys Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.